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Impaired energy metabolism is a feature of Congestive Heart Failure (CHF). Iron deﬁciency has been shown to reduce energy
production in the cell in animals and humans. Iron deﬁciency is common in both Chronic Kidney Disease (CKD) and in CHF.
Recent studies suggest that iron deﬁciency is an independent risk factor for mortality in CHF. Studies of correction of the anemia
with intravenous (IV) iron in both CKD and CHF have shown an improvement in the anemia and, in some cases, in the renal
function as well. Some CHF studies of correction of the iron deﬁciency have shown an improvement in cardiac function and
structureaswellasinexercisecapacityandqualityoflife.Thisoccurred independentofwhetherornottheyhadanemia,suggesting
thattheirondeﬁciency itselfmaybeindependently contributingtotheworseningoftheCHF andCKD.Iffuture long-termstudies
conﬁrm the safety and eﬃcacy of IV iron in the treatment of iron deﬁciency in CKD and CHF, this will become a new addition to
the therapeutic armamentarium of the cardiorenal syndrome, and parameters of iron deﬁciency will become part of the routine
measurements performed in both CKD and CHF whether or not the patient is anemic.
1.Introduction
Impaired energy metabolism is a feature of the Congestive
Heart Failure (CHF) syndrome [1]. The failing heart is an
energy-starved heart, and energy-sparing treatments such
as beta blockers, ACE inhibitors, or Angiotensin II blockers
improve the prognosis [1]. Iron metabolism is crucial in
all aspects of energy production in the body [2–4]a n d
is particularly important for cells that are characterized
b yh i g he n e r g yd e m a n d ss u c ha ss k e l e t a lm y o c y t e sa n d
cardiomyocytes [2–4]. Iron has the ability to shuttle between
two oxidative states, (ferric and ferrous iron) which makes
it an eﬃcient cofactor for several enzymes and the catalyst
of numerous biochemical reactions [2–4]. The ferrous form
Fe II can donate electrons while the Fe III form can accept
electrons. Iron plays a crucial role in oxygen transport
(as a component of hemoglobin (Hb)), oxygen storage
(as a component of myoglobin), and oxidative metabolism
(as a component of oxidative enzymes and respiratory chain
processes).
It is also involved in the synthesis and degradation of
lipids, carbohydrates, DNA,and RNAand inthe metabolism
of collagen, tyrosine, and catecholamines [2–4].
Therefore, iron deﬁciency can impair oxidative metabo-
lism, cellular energetics, and cellular immune mechanisms.
Iron deﬁciency in experimental models causes a major dis-
ruptioninenergyproductionandcanleadtocardiacdamage
and dysfunction [5, 6]. Even in otherwise normal people,
iron deﬁciency can reduce endurance and optimal energetics
of skeletal muscle even if no anemia is present initially [7–
10].
There is growing evidence that iron deﬁciency is com-
mon in CHF and may contribute to the increased mortality
in this condition and that correction of the iron deﬁciency
with IV iron can improve both cardiac and renal function,
symptoms of CHF, exercise endurance, inﬂammation, and
quality of life and may reduce hospitalization. However,
more studies are needed to conﬁrm this. Thus, correction of
iron deﬁciency could become an important new addition to
the treatment of the cardiorenal syndrome.2 International Journal of Nephrology
2.Prevalenceof IronDeﬁciencyin
CHFwithand withoutAnemia andIts
PrognosticSigniﬁcance
The prevalence of iron deﬁciency in CHF depends on how
iron deﬁciency is deﬁned. If merely deﬁned as a % Trans-
ferrin Saturation (%TSat) of <16, it was found in one
preliminary study in 78% of anemic and 61% of nonanemic
CHF patients, whereas if it was deﬁned as a %TSat of <16
and a serum ferritin of 30–100ug/L, it was found in only
15% of anemic and 20% of nonanemic CHF patients [11].
In one study of CHF patients, a low serum iron was found in
31% of anemics and 7% of nonanemics, a low serum ferritin
in 21% of anemics and 7% of nonanemics, and at least one
of the two in 43% of anemics and 15% of nonanemics [12].
In a study of CHF patients undergoing coronary stenting,
31% had iron deﬁciency as judged by a low serum iron
and increased Total Iron Binding Capacity. Iron deﬁciency
anemia strongly predicted cardiac mortality [13]. In another
study of anemia in CHF, about half the patients had serum
iron levels below normal, and the great majority of anemic
patients also had an elevated soluble transferrin receptor
(a quite dependable measure of iron deﬁciency) [14]. In a
study of anemia in severe CHF,markedly reduced iron stores
in the bone marrow were found in 73% of the cases [15]
even though the great majority had a normal serum ferritin
level.
In the largest observational study done to date [16], a
prospective observational study, 546 patients with stable
systolicmildtosevereCHFwerefollowedforameanof731±
350days.Patientswithsevererenaldiseasewereexcludedand
indeed the mean calculated glomerular ﬁltration rate (GFR)
was 80.5mL/min/1.73sqm. Iron deﬁciency was deﬁned as
a serum ferritin <100ug/L or 100–300ug/L with %TSat
<20%. The prevalence of iron deﬁciency was 37 ± 4% for
t h ee n t i r ep o p u l a t i o na n dw a s3 2± 4% in the nonanemics
and 57 ± 10% in the anemics (anemia was deﬁned as a
Hb < 12g/dL in women and <13g/dL in men). Even in
those with mild heart failure as judged by NYHA I and II,
the frequency of iron deﬁciency did not drop below 30%.
The prevalence of iron deﬁciency was related to the female
sex, the severity of the CHF as judged by the New York
Heart Association class (NYHA) and by the Beta Natriuretic
Peptide (BNP), and the severity of the inﬂammatory process
as judged by C Reactive Protein (CRP). In univariate
models, the 3-year survival rate was 59% in the iron
deﬁciency group and 71% in the noniron deﬁciency group
(P = .0006). In multivariable analysis, iron deﬁciency was
considered an independent predictor of all-cause mortality
after adjustment for confounders including anemia and
severity of the CHF. The eﬀect was seen as early as 6
months.Theinclusionofanemiainthemultivariablemodels
did not change signiﬁcantly the signiﬁcance suggesting that
iron deﬁciency may be a stronger prognostic indicator of
survival than anemia. Thus, iron deﬁciency, independent of
anemia and cardiac function, is related to a poor outcome in
CHF.
Therefore absolute iron deﬁciency (deﬁned as a serum
ferritin<100ug/Land%TSat<20%)orfunctionalirondeﬁ-
ciency (deﬁned as a serum ferritin>100ug/L and %TSAT<
20%) are commonly seen in CHF patients with anemia or
even without anemia and are associated with an increased
mortality.
3.Does Correctionofthe Anemia with
ErythropoiesisStimulatingAgents(ESA)
inPatientswithCHFImprovetheCHF?
Several metaanalyses which included nonplacebo controlled
studies, and placebo-controlled studies of ESA along with
oral or IV iron have shown improvement in many aspects
ofCHF withoutcausing undesirable side eﬀects[17–21].But
all of these studies have been small and/or short term and
a total of about only 700 patients in all have been studied.
On the other hand, in a larger metaanalysis of ESAtreatment
in CHF that included the CHF patients in the TREAT study,
the Reduce Cardiovascular Events with Aranesp (TREAT)
study in diabetics with renal insuﬃciency, pooled data from
9placebo-controlled studiesenrolling a totalof2,039anemic
CHF patients treated with ESA was associated with a neutral
eﬀect on both mortality and nonfatal heart failure events
[22]. Therefore, the value of ESA in the anemia of CHF is
still uncertain.
4.Growing ConcernabouttheSafetyofESA
There is growing concern about the safety of ESA because
of the hypertension, increased thrombotic events, and other
cardiovascular complications and possible increased cancer
risk seen with its use in CKD [23–25] so thatthere is growing
interest in the use of IV iron alone or at least as the ﬁrst step
in the treatment of the anemia of CKD and CHF before an
ESA is started.
5.Does CorrectionofIron Deﬁciencyin
PatientswithCHFImprovetheCHF?
Six studies where intravenous (IV) iron has been used
in iron-deﬁcient CHF patients have been performed, but
only two were placebo-controlled double blind studies
[26, 27].
In one of these two studies [26], a single center study,
40 patients received either IV iron as iron sucrose (Venofer,
Vifor Int Zurich) 200mg a week for 5 weeks or a placebo
infusion. Their Hb was <12.5d/gL for men and <11.5g/dL
for women. Their initial serum ferritin was<100ng/mL
and/or %TSat ≤20%. At 6-month followup there was a
signiﬁcant improvement in the Hb levels, NYHA, Left
Ventricular Ejection Fraction (LVEF), 6 minute walk test
(6MWT), hospitalization rate, Minnesota Living with Heart
Failure Questionnaire Quality of Life (MLHFQ) scale, cre-
a t i n i n ec l e a r a n c e ,C - R e a c t i v ep r o t e i n ,a n dN Tp r oB N P ,a
slowing of the heart rate, and lower diuretic requirements in
the treated compared to the control group.International Journal of Nephrology 3
In the other double blind placebo-controlled study, this
one a multicenter study (The FAIR-HF study [27]), the
patients were randomly assigned to IV ferric carboxylase
200mg (Vifor Int Zurich) versus matching control in a 2:1
ratio. A total of 459 subjects with chronic left ventricular
systolic dysfunction were studied. Their initial serum fer-
ritin was <100ug/L or 100–299ug/L if %TSat was <20%.
The mean initial Hb was between 9.5 and 13.0g/dL. The
exclusion criteria were uncontrolled hypertension, other
signiﬁcant heart disease, or impaired liver or renal function.
They were given enough iron to maintain the %TSat at 25–
45% and serum ferritin at 400–800ng/mL. The primary end
points were patient self assessment and investigator-assessed
NYHA at 6 months. Secondary end points were 6-minute
walk and quality of life (QOL) as assessed by the Kansas
City Cardiomyopathy questionnaire and the European EQ
5D QOL visual analogue scale. Safety outcomes included
hospitalizationsanddeath.TheinitialHblevelwas11.9g/dL,
mean serum ferritin 50–60ug/mL, and mean transferrin
saturation 17%. At week 24 in the IV iron group the serum
ferritinhad increased to313±13versus74±8ng/mL.%TSat
to 29 ± 1v e r s u s1 9± 1% and Hb to 13.0 ± 0.1v e r s u s
12.5 ± 0.1g/dL. All these were signiﬁcant diﬀerences from
placebo. The use of IV iron was associated with signiﬁcant
improvements in NYHA functional class, 6-minute walk
distance (mean study eﬀect 35.8m) EQ5 patient global
assessment scale, and Kansas City QOL scale. Renal function
improved signiﬁcantly only in the treated group. At 4 weeks
the diﬀerence in GFR between the active treatment and
placebo was 2.5 ± 1.5mL/min/1.73sqm, at 12 weeks it was
3.0 ± 1.3 ,a n da t2 4w e e k si tw a s4 .0 ± 1.7mL/min/1.73sqm.
The magnitude of all the treatment eﬀects did not diﬀer
in subjects with or without anemia (deﬁned as a Hb ≤
12g/dL). The treatment eﬀects were also not related to the
initial age, presence of diabetes, initial severity of the CHF,
renal function, or ferritin levels. Although there was no
diﬀerence in ﬁrst hospitalization for cardiovascular causes
or death in the treated and nontreated, there was a trend
to improvement in the two. There was no evidence of any
adverse eﬀects of the IV treatment compared to placebo.
The improvements compared to controls were seen quite
rapidly, even within the ﬁrst month. The fact that the
improvement was similar in the treated group unrelated
to the initial Hb suggests that part of the eﬀect of the
IV iron might have been due to its direct eﬀect on body
tissues.
In the Ferric Iron Sucrose in Heart Failure study
(FERRIC-HF) [28], a randomized open label observer blind
study lasting 4 months in 35 patients with CHF who were
either anemic (Hb < 12.5g/dL) or non-anemic (Hb 12.5–
14.5g/dL) but all of whom were iron deﬁcient, patients
were assigned in a 2:1 ratio to receive 16 weeks of IV
iron sucrose (Venofer) or to a control group. Unlike the
previous 2 studies, treatment did not result in a signiﬁcant
improvement in Hb levels. Nevertheless there was a trend
toward an improvement in exercise tolerance as judged by
peak VO2 and a signiﬁcant increase in peak VO2/kg in the
treated group but not in the control group. There was also
a trend toward an increase in absolute exercise duration
and percentage change in exercise duration in the iron
group but not in the control group. There were signiﬁcant
improvements in NYHA,patientglobal assessment, MLHFQ
quality of life scale, and fatigue score in the iron group.
All the changes were more pronounced in the anemic
group than the nonanemic group. The heart rate fell in
the anemic group only. The changes in peak VO2 were
related to changes in %TSat but not to Hb in anemic
patients suggesting therefore, as did the previous paper, that
the improvement in CHF was due at least partially to the
correction of the iron deﬁciency and not to an increase in
Hb.
Bolger et al. [29] treated 16 CHF patients with intra-
venous iron sucrose (Venofer-Zurich) in an uncontrolled
openlabelstudy.The Hbwas<12g/dLandtheserumferritin
<400ug/L. Patients were treated for 12–17 days and followed
for 92±6 days. Treatment was associated with an increase in
the Hb level (11.2 ± 0.7t o1 2 .6 ± 1.2g/dL) and a signiﬁcant
improvement in the NYHA class, MLHFQ score, and 6-min
walk distance (6MWD). There was a trend toward improved
renal function.
Usmanov et al. [30] treated 32 moderate to severe
(NYHA III and IV) CHF patients and moderate renal failure
(mean serum creatinine 2.3mg/dL) with IV iron (Venofer)
in an uncontrolled study for 26 weeks. The inclusion Hb
was <11g/dL. Iron sucrose was given in a dose of 100mg 3
times a week for 3 weeks and then once weekly for 23 weeks
(total dose 3200mg of iron). The mean Hb increased from
10.7 ± 0.4t o1 3 .7 ± 0.4 in NYHA III and from 9.4 ± 0.6
to 12.7 ± 0.08 in NYHA IV. The mean serum iron, %TSat,
ferritin were all lower than normal before treatment and
increased to normal after treatment. There was a signiﬁcant
improvement in NYHA in the NYHA III group but not in
the NYHA IV group. Initially there was evidence of severe
cardiac hypertrophy and dilation and reduced LVEF, and
these improved after 6 months of IV treatment, but more so
in NYHA III than in NYHAIV. There was no change in renal
function.
In a sixth study [31]w h i c he x a m i n e dt h ee ﬀect of IV
iron in bone marrow-conﬁrmed iron deﬁciency anemia in
severe CHF with anemia, 8 patients were randomly assigned
to treatment with IV iron 300mg once weekly for 6 weeks
(total 1800mg) and 8 others to the same treatment along
with 50ug darbepoetin once weekly for six weeks. Over the
entire 3 months of treatment and followup, the Hb increased
by 2.4g/dL in the IV iron alone group and by 2.8g/dL in the
group with both agents. This small study suggests that the
IV iron is a major contributor to the anemia. This study and
that of Usmanov et al. [30] mentioned above also point out
thathigherdosesofIVironleadtogreaterHbresponsesthan
lowerdoses,thatis,thereisadoseresponse relationship. This
has been seen in CKD as well [32].
These studies suggest that the anemia of many CHF pa-
tients can be improved by IV iron alone. On the other hand,
in several studies of anemia treatment in CHF [33, 34], the
u s eo fo r a li r o ni na n e m i cC H Fp a t i e n t sf o ro n ey e a rw a sn o t
associated with any increase in Hb or improvement in any
CHF parameters.4 International Journal of Nephrology
6.What Are the Causesof
IronDeﬁciencyinCHF?
6.1. Chronic Kidney Disease (CKD). CKD is associated with
reduced production of Erythropoietin (EPO) in the kidney.
The renal damage seen in CHF is probably mainly due to
reduced renal blood ﬂow caused by the reduced cardiac
output causing hypoxic renal damage [21, 35].
Iron deﬁciency is also common in CKD [36–39]. About
half the cases of iron deﬁciency are absolute iron deﬁciency
with low %TSat and low serum ferritin (usually associated
with decreased iron stores), and about half are relative
iron deﬁciency with low %TSat and normal or elevated
serum ferritin (often associated with normal or increased
iron stores). The iron deﬁciency is frequently associated
with reduced iron deposits in the bone marrow [39, 40].
Because CKD is an inﬂammatory condition, increased
cytokines may also contribute to the anemia and to the iron
deﬁciency(seebelow).The useof Erythropoiesis Stimulating
Agents (ESAs) in CKD will also rapidly reduce iron stores.
The gastrointestinal causes of anemia in CKD are discussed
below.
6.2. Elevated Cytokines Causing Abnormalities in EPO and
Iron Metabolism. These cytokinesare elaborated inCHFand
CKD, especially Tumour Necrosis Factor alpha (TNF α)a n d
interleukin-6 (IL-6). They can cause four haematological
abnormalities [41, 42]:
(a) reduced EPO production in the kidney leading to
inappropriately low levels in the blood for the degree
of anemia present,
(b) reduced erythropoietic response of the bone marrow
to ESA,
(c) hepcidin-induced failure of iron absorption from the
gut, and
(d) hepcidin-induced trapping of iron in iron stores in
the macrophages and hepatocytes.
Hepcidin [29, 30] is a protein released from the liver by
IL-6. It inhibits the protein ferroportin which is found in the
gastrointestinal tract and in macrophages and hepatocytes
and is responsible for the release of iron from these three
types of cells into the blood. Therefore if ferroportin is
inhibited,gastrointestinal ironabsorptionis diminished, and
iron is also not released from its storage in macrophages
and hepatocytes. This results in a low serum iron leading to
decreased delivery of iron to the bone marrow and therefore
irondeﬁciencyanemia,eveninthepresenceofadequatetotal
iron stores, the so-called functional iron deﬁciency. Since
hepcidin is ﬁltered and removed in the kidney, its levels
increase in CKD, which can also partly explain the iron
deﬁciency in CKD [43] and in CHF in whom about half
the patients have renal insuﬃciency as judged by a creatinine
clearance of <60mL/min/1.73sqm [44].
6.3. Gastrointestinal Problems. There are many other causes
of iron deﬁciency in CKD including reduced iron intake
due to low protein diets and anorexia, gastrointestinal blood
loss due to uremia causing platelet dysfunction, as well as
esophagitis, gastritis, tumors, platelet inhibitors and antico-
agulants [45], and phosphate binders which can also bind
iron. It has also been found that proton pump inhibitors
such as omeprazole, which are extremely widely used, reduce
iron absorption [46]. In addition, CHF itself can cause
intestinal cell dysfunction due to bowel edema and other
causes [47]. Frequent removal of blood for blood tests may
also contribute to the anemia.
Also, as mentioned earlier, both CKD and CHF are in-
ﬂammatory conditions with increased cytokines which can
cause hepcidin-induced iron deﬁciency.
7.The CellularEffectsof IronDeﬁciency
Iron is indispensable for life, serving as a metal cofactor for
many enzymes, either nonheme iron-containing proteins or
hemoproteins. Hemoproteins are involved in many crucial
biologic functions including oxygen binding (hemoglobins),
oxygen metabolism (oxidases, peroxidase, catalases, etc.),
and electron transfer (cytochromes). Many nonheme iron-
containing proteins catalyze key reactions involved in energy
metabolism and DNA and RNA synthesis. In addition,
iron-containing proteins are required for the metabolism of
collagen, tyrosine, and catecholamines [2–4].
Experimental studies in animals have shown that severe
iron deﬁciencycancause diastolicdysfunction and heart fail-
ure with pulmonary congestion, left ventricular hypertrophy
and dilation, cardiac ﬁbrosis, a reduction in the erythro-
poietin levels and a worsening of the molecular signaling
pathways (as measured by cardiac STAT 3 phosphorylation),
an increase in the inﬂammatory cytokine TNFα,a n dp r o -
teinuria [5]. This defect in the molecular signaling pathway
in iron deﬁciency may be critical for the transition from
adaptive cardiac hypertrophy to cardiac dysfunction in long-
term irondeﬁciency.In addition,iron deﬁciencyin rat hearts
causes mitochondrial ultrastructural aberrations, irregular
sarcomere organisation, and release of cytochrome C [6].
Iron may have anti-inﬂammatory eﬀects. Compared to
haemodialysis patients taking EPO alone, those taking EPO
and IV iron had lower proinﬂammatory TNFα levels and
higher anti-inﬂammatory cytokine IL-4 levels as well as
lower levels of total peroxide (a marker of free radical
concentration) [48].
8.Oral versusIV Iron inCKD
As mentioned earlier, in patients with CKD who are anemic,
iron deﬁciency has been found in at least half the patients
using either blood tests [36–39] or bone marrow biopsies
[39, 40] ,a n dI Vi r o na l o n em a yi n c r e a s et h eH bs i g n i ﬁ c a n t l y
[39, 40, 49–51]. In most studies comparing oral to IV iron
in CKD, IV iron has been found to produce a greater Hb
response than oral iron with less side eﬀects [32, 50, 51],
and many patients can reach a target Hb of 11.0 to 12g/dL
with this therapy alone and therefore avoid the use of ESA
altogether [32, 40, 49–51]. Although there has been concernInternational Journal of Nephrology 5
about IV iron causing renal disease [52], this has not been
conﬁrmed by other studies [32, 39, 40, 49–51]. Indeed, in
one study renal function in CKD improved in the IV iron
group but not in the oral iron group [50]. In most studies
c o m p a r i n go r a lt oI Vi r o ni nC K D ,I Vi r o nh a sb e e nf o u n d
to produce a greater Hb response with less side eﬀects [51].
As mentioned above, in several studies of anemia treatment
in CHF [33, 34], the use of oral iron in anemic CHF patients
for one year was not associated with any increase in Hb or
improvement in any CHF parameters.
9.IronDeﬁciencyand Thrombocytosis
The incidence of venous thromboembolism is greatly
increased in CHF [53] ,a n di n d e e dC H Fi sc o n s i d e r e dt o
be a hypercoagulable state [54]. Could iron deﬁciency in
these CHF patients be one cause of this? Iron deﬁciency
can cause thrombocytosis [55] which can lead to increased
thrombosis,atherosclerosis,andincreasedmortality[56,57].
CorrectionoftheirondeﬁciencywithIVironinEPO-treated
dialysis patients reduced the platelet count signiﬁcantly [58].
This may be important, since thrombocytosis may be one
of the missing links in causing the increased incidence of
cardiovascular eﬀects of EPO in CKD [56, 57] and in cancer
[59,60].HighdosesofEPOinCKDare associated withmore
iron deﬁciency, more severe thrombocytosis, and increased
mortality [56, 57]. Iron deﬁciency also increases oxidative
stress [61].
10.The Administrationof IroninAnemic and
Nonanemic People
Beutler showed over ﬁfty years ago that iron deﬁciency can
negatively aﬀect enzymes throughout the body with or even
without actual anemia being present [7]. He also showed
in a randomised double-blind placebo-controlled crossover
study that oral iron can improve fatigue in anemic and also
in nonanemic iron deﬁcient women [7], and this has been
subsequently conﬁrmed by others [8–10]. All these studies
suggest that iron has a speciﬁc eﬀect on the cells in addition
to its ability to make hemoglobin.
11.What AssaysPredictthe Responseto
IV Iron?
The two commonly used tests to detect iron deﬁciency are
a low % Transferrin Saturation (%TSat) and a low serum
ferritin. But though they are low in absolute iron deﬁciency
where iron stores are low, the %TSat may become low but
the serum ferritin high in the presence of inﬂammation and
thereforemaynotreﬂectironstatusaccurately.Thisistheso-
called anemia of chronic disease. In fact, iron stores may be
elevated in inﬂammation in the face of a low %TSat, and the
serum ferritin may be elevated in the presence of depleted
iron stores. There is no test that can predict with great
accuracy the degree of response to IV iron in patients taking
ESA in CKD [39, 62, 63]. However, generally in CKD the
%TSat is a better predictor than ferritin, and the reticulocyte
Hb is better than %TSat [62, 63], but the diﬀerences are
probably not large enough to be clinically useful.
12.Concernsaboutthe Safetyof Iron
There is some evidence in hemodialysis patients that IV
iron treatment is associated with a lower mortality [64–
66]. Recently, in CKD patients not on dialysis, it was
found that the lower the %TSat the higher the mortality,
again raising the possibility that iron deﬁciency may be
a common and reversible cause of severe cardiovascular
disease [67]. However, IV iron can cause oxidative stress
[68], and therefore long-term controlled studies of IV iron
are needed to evaluate the eﬀects of IV iron in CKD, as in
CHF. Although there has been concern about increased iron
stores being associated with increased risk of coronary heart
disease [69] this has not been conﬁrmed by others [70, 71],
and the issue is still controversial. But the implications of the
presence of iron deﬁciency in CHF are enormous since, as
mentioned above, a high percentage of patients with CHF,
whether anemic or not anemic, have true or functional iron
deﬁciency. If correction of this iron deﬁciency proves both
safe and eﬀective, this could be a new and useful addition to
the treatment of CHF.
13.HowDoes Anemia CauseorWorsenCHF?
It appears that anemia can exacerbate heart failure through
a vicious circle in which tissue hypoxia and release of nitric
oxidecausesperipheralvasodilation whichleadstodecreased
blood pressure which then causes increased sympathetic
activation, renal vasoconstriction, reduced renal function,
and activation of the renin-angiotensin aldosterone system
[21, 35]. This in turn leads to ﬂuid retention, left ventricular
hypertrophy and dilatation, worsening heart failure, release
of BNP arising from stress on the myocardium, and, to
complete the vicious circle, further anemia.
14.The CardiorenalAnemia Syndrome
About 10 years ago, we described the Cardio Renal Anemia
syndrome (CRA syndrome) [72]. Our hypothesis was that
there is a vicious circle operating between Congestive Heart
Failure (CHF), Chronic Renal Failure, and anemia where
each might cause or worsen the other. The correction of
anemiawasamajorpartofthisviciouscircleinthereduction
of the severity of the CHF. In view of the possible inde-
pendent association of iron deﬁciency and cardiac failure,
renal failure, and anemia we now suggest renaming the
syndrome the CRAID syndrome, the Cardio Renal Anemia
Iron Deﬁciency Syndrome.
15.Conclusion
It is daunting to consider that the use of something as
simple asIVironin CHFpatientswith absoluteorfunctional
iron deﬁciency may have an important role to play in the
treatment ofalarge percentageofCHFpatients,both anemic6 International Journal of Nephrology
andnonanemicandwithorwithoutCKD.Clearly,long-term
adequately-powered placebo-controlled studies of IV iron
in CHF with hard endpoints are needed. In the meantime,
in the assessment of patients with CKD and/or CHF, the
laboratory markers of iron deﬁciency should be routinely
measured. Faced with a patient with absolute or functional
iron deﬁciency with or without anemia who has CHF with
or without CKD, it is the authors’ opinion that a trial
of IV iron might reduce signiﬁcantly the severity of these
conditions and should be administered before an ESA is
started.
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